FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics
  PTC Therapeutics has received FDA approval for its innovative gene therapy targeting Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, a rare genetic disorder affecting dopamine synthesis. This therapy, the first of its kind for this condition, promises to improve motor and cognitive functions in affected children, marking a major breakthrough in rare disease treatment and a...
0 Comments 0 Shares 139 Views 0 Reviews
Sponsored